icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Anti-viral Proof of Concept Study of Miravirsen, an OligonucleotideTargeting miR-122, in Treatment Na´ve Patients with Genotype 1 Chronic HCV Infection
 
 
  Reported by Jules Levin
AASLD Nov 5-8 2011 SF
 
AASLD: MicroRNA Drug Safe in Ongoing HCV Study - (11/21/11)
 
H. L. A. Janssen1; H. W. Reesink2; S. Zeuzem3; E. Lawitz4; M. Rodriguez-Torres5; A. Chen6; C. Davis6; B. King6; A. A. Levin6; M. R. Hodges6 1Erasmus MC University Hospital, Rotterdam, The Netherlands 2Academic Medical Center, Amsterdam, The Netherlands 3J.W. Goethe University Hospital, Frankfurt, Germany 4Alamo Medical Research, San Antonio, TX, United States 5Fundacionde Investigacionde Diego, San Juan, Puerto Rico 6Santaris PharmaA/S, San Diego, CA, United States

hepDart1.gif

hepDart2.gif

hepDart3.gif

hepDart4.gif

hepDart5.gif

hepDart6.gif

hepDart7.gif

hepDart8.gif

hepDart9.gif

hepDart10.gif